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OBJECTIVE: Our aim was to evaluate the Japan Gastroenterological Endoscopy Society criteria for endoscopic
submucosal resection of early gastric cancer (EGC) based on the experience in a Brazilian cancer center.
METHODS: We included all patients who underwent endoscopic submucosal resection for gastric lesions
between February 2009 and October 2016. Demographic data and information regarding the endoscopic
resection, pathological report and follow-up were obtained. Statistical calculations were performed with
Fisher’s exact test and chi-square tests, with 95% confidence intervals.
RESULTS: In total, 76% of the 51 lesions were adenocarcinomas, 16% were adenomas, and 8% had other
diagnoses. The average size was 19.9 mm (±11.7). The average procedure length was 113.9 minutes (±71.4).
The complication rate was 21.3%, with only one patient who needed surgical treatment (transmural
perforation). Among the adenocarcinomas, 39.5% met the classic criteria for curability, 31.6% met the
expanded criteria and 28.9% met the criteria for noncurative resection. Analysis of the indication criteria and
curability revealed differences among cases with ‘‘only-by-size’’ expanded criteria (64.28%), other expanded
criteria (40%) and classic criteria (89.47%), with a p-value of 0.049. During follow-up (15.8 months; ±14.3),
86.1% of the EGC patients had no recurrence. When well-differentiated and poorly differentiated lesions or
lesions included in the classic and expanded criteria were compared, there were no differences in recurrence.
The noncurative group presented a higher recurrence rate than the classic group (p=0.014).
CONCLUSION: These results suggest that the Japanese endoscopic submucosal resection criteria might be useful
for endoscopic treatment of EGC in Western countries.
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’ INTRODUCTION
Early gastric cancer (EGC) refers to cases in which tumor
invasion is limited to the mucosa and submucosa, irrespective
of lymphatic involvement. In tumors restricted to the mucosal
layer (intramucosal carcinoma), the rate of lymph node
metastasis is less than 5%, while in lesions involving the
deep submucosal layer, the rate is as high as 20% (1).
The presence of lymph node metastasis is one of the main
factors contributing to patient prognosis (2,3). For this reason,
a gastrectomy with lymphadenectomy is considered the
gold standard for the treatment of EGC (4). The five-year
survival rate for patients undergoing this surgery reaches
99% and 96% for those with mucosal and submucosal
lesions, respectively (5); however, there is a high morbidity
rate and an important reduction in quality of life are also
related to this procedure (6).
The first descriptions of endoscopic resection for ECG
were made in the 1980s, and currently, these techniques are
accepted as an option for ECG with a low risk of lymph node
metastasis (7). In Japan, where the incidence and the early
detection rates of gastric cancer are high, the initial treatment
of choice for ECG is endoscopic resection with endoscopicDOI: 10.6061/clinics/2018/e553s
Copyright & 2018 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on February 10, 2018. Accepted for
publication on June 7, 2018
Commemorative Edition: 10 years of ICESP
1
ORIGINAL ARTICLE
submucosal dissection (ESD) (8-11). The Japanese Gastro-
intestinal Endoscopy Society has established criteria for
endoscopic resection for EGC (12). The classic criteria were
initially established for endoscopic mucosal resection (EMR),
also known as mucosectomy, and included well-differentiated
lesions that were smaller than 2 cm and lacked ulceration
and vascular involvement. With the development of the
technique of ESD, experience revealed that these criteria are
restrictive, leading to unnecessary surgery (13). Then, expan-
ded criteria were defined, including well-differentiated
intramucosal carcinoma of any size without ulceration,
well-differentiated intramucosal carcinoma smaller than
3 cm with ulceration, and undifferentiated intramucosal
carcinoma smaller than 2 cm without ulceration. A resection is
considered curative when the lesion is removed in one single
specimen (en-bloc resection), with free margins and without
vascular involvement, with invasion up to the superficial
submucosa (500 micra - sm1) for well-differentiated lesions
and with intramucosal invasion for undifferentiated lesions.
These recommendations have not yet been validated in
Western countries, as the epidemiology of gastric cancer in
this part of the world is very different and the experience
with these procedures is limited (12).
The aim of this study was to evaluate the results in terms
of cancer recurrence of the ESD of EGC using the classic and
expanded criteria.
’ MATERIALS AND METHODS
All patients with gastric lesions who underwent ESD
between February 2009 and October 2016 were included in
the analysis. The demographic and preprocedural data and
the information regarding the endoscopic resection, patho-
logical report and follow-up were recorded prospectively in
our institutional database and then retrospectively reviewed.
The following epidemiological, clinical, and endoscopic
data were retrospectively retrieved: sex, age, localization of
the lesion, histology provided by endoscopic biopsy, proce-
dure duration, complications, length of hospital stay (days) and
follow-up data. All lesions were classified according to the Paris
endoscopic classification of superficial neoplastic lesions (14).
The ESD specimens were evaluated with regard to histo-
logical type, depth of invasion, lateral margins, size of the
lesion, and vascular and perineural invasion. In cases of
uncertainty, a pathological review was conducted. The tumor
was classified according to the Japanese classification of
gastric carcinoma criteria (15).
En-bloc resection was defined when during the ESD
procedure it was possible to resect the lesion in a single
specimen, with no need for complementary EMR. Complete
resection was defined as the histological absence of the
tumor in the lateral and deep margins of the specimen. When
the tumor fulfilled the classic or expanded criteria and a com-
plete resection with no vascular involvement was achieved
by ESD, the cancer was considered cured. The local recur-
rence was defined when, during the available follow-up after
ESD, a new malignant gastric lesion was found in the same
location or when the patient underwent a gastrectomy after
endoscopic resection and there were still tumor cells in the
same stomach region. We did not distinguish between resi-
dual or recurrent tumors.
Statistical analysis was performed with OpenEpi Software
to compare the two groups of patients with adenocarci-
noma lesions with chi-square tests and Fisher’s exact test (16).
One cohort was defined by the indication criteria for the
resection (expanded indication: well-differentiated, intramu-
cosal,42 cm; expanded indication by other parameters; and
classic indication), with the outcome of interest being cur-
ability. The other cohort was divided based on the curability
criteria (classic criteria; expanded criteria; and noncurative
criteria) with the outcome of interest being recurrence. A 95%
confidence interval was used.
’ RESULTS
In total, 47 patients (29 men – 61.7%; 18 women – 38.3%)
were included, with a mean age of 68 years (range 42-
90 years). Three of the patients underwent more than one
resection, for a total of 51 ESD procedures. The mean tumor
size was 20.0 mm (±11.7), with a mean procedure dura-
tion of 113.9 minutes (±71.4) and a median hospital stay of
3.2 days (±2.8). The antrum was the most common lesion
location (43.1%), and the body was the second most common
lesion location (33.3%). In terms of histologic type, we found
38 adenocarcinomas (76%), 8 adenomas (16%) and 4 lesions
with other diagnoses (8%). Paris type IIa was the most pre-
valent macroscopic type (29.4%). Ten patients had complica-
tions (21.2%), with 5 cases of bleeding (10.6%) and 5 cases of
muscular perforation (10.6%). Nevertheless, only one patient
(2.1%) needed surgical treatment due to transmural perfora-
tion. The other four cases of perforation and five cases of
bleeding were managed with clips. There was no mortality.
Other detailed data are shown in Table 1 and Table 2.
Among the 38 adenocarcinomas, 34 were well differen-
tiated (89.5%), and 4 (10.5%) were poorly differentiated. The
rates of en-bloc and complete resection were 92.1 and 73.6%,
respectively. There was no difference in the complete resec-
tion rate between the lesions meeting the classic and expan-
ded criteria (p=0.07), as shown in Table 2. In 27 cases (71.0%),
the cancer was considered cured by ESD, 15 (39.5%) of which
met the classic criteria and 12 (31.6%) of which met the
expanded criteria. The other 11 cases (28.9%) had noncura-
tive resections. Analyzing the indication criteria and cure
rates, we found differences among the patients who achie-
ved curative resection with the expanded criteria of a
Table 1 - Characteristics of the lesions.
Criteria Data
Median tumor size 19.98 mm (±11.7)
Localization
Cardia 7 (13.7%)
Body 17 (33.3%)
Body-antrum 2 (3.9%)
Incisura angularis 3 (5.9%)
Antrum 22 (43.1%)
Paris Classification
Is 7 (13.7%)
IIa 15 (29.4%)
IIb 2 (3.9%)
IIc 9 (17.6%)
IIa+IIc 13 (25.5%)
Other 5 (9.8%)
Histology
Adenocarcinoma 38 (76.0%)
Well-differentiated 34 (68.0%)
Poorly differentiated 4 (8.0%)
Adenoma 8 (16.0%)
Neuroendocrine tumor 3 (6.0%)
Inflammatory fibroid polyp 1 (2.0%)
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well-differentiated intramucosal adenocarcinoma larger than
20 mm (64.3%), other expanded criteria (40.0%) and classic
criteria (89.5%), with a p-value of 0.049. When conducting
pairwise comparisons of these groups of patients, we found
that the cure rate was higher in patients in whom the classic
criteria were met (89.5%) than in patients in whom ‘‘other’’
expanded criteria were met (40.0%) (p=0.042), as shown in
Table 3.
During the available follow-up (median of 15.7 months;
±14.3), 31 patients with ECG (83.8%) were free from recurrence.
There was one patient lost to follow-up. Of the five
patients defined as experiencing recurrence, one had a major
perforation during ESD and needed surgery (the patho-
logical analysis showed muscular involvement), and the
other three developed recurrence in the resection site, all of
which were managed by gastrectomy. None of the patients
presented with distant metastasis or death related to the
lesion during follow-up. In addition to the group of patients
who experienced recurrence, three other patients underwent
gastrectomy; one patient met the noncurative criteria, one
met the expanded curative criteria parameters and one met
the classic curative criteria parameters. These three patients
did not have residual carcinoma in the surgical specimen.
Five patients in the noncurative group were not managed
with gastrectomy due to high surgical risk related to com-
orbidities, and none of them presented with recurrence
during follow-up. Comparing well-differentiated and poorly
differentiated lesions, we found no difference in terms of
recurrence between these groups (p=0.46). In contrast, when
comparing the recurrence outcome between the lesions
included in the classic, expanded and noncurative criteria,
there was a difference among the three groups (p=0.014).
When we performed pairwise comparisons of these groups
(Table 3), we found a difference in terms of recurrence only
Table 2 - Characteristics of the ESD procedure.
Parameter Data
Median surgery length 113.91 min (±71.4)
Median hospital stay 3.24 days (±2.7)
En-bloc resection 35 (92.1%)
Complete resection 28 (73.7%)
Classic indication criteria 16 (84.2%) p=0.07
Expanded indication criteria 12 (63.1%)
Complications
Bleeding 5 (10.6%)
Minor perforation 4 (8.5%)
Major perforation 1 (2.1%)
Table 3 - Cure criteria comparison in adenocarcinoma cases.
Criteria Data
Curative criteria
Classic criteria 15 (39.5%)
Expanded 12 (31.6%)
Noncurative 11 (28.9%)
Indication criteria
Expanded indication: well-differentiated, intramucosal, 42cm 14 (36.8%)
Expanded indication by other parameters 5 (13.2%)
Classic indication 19 (50.0%)
Cure by indication criteria
Expanded indication: well-differentiated, intramucosal, 42cm 9 (64.3%) p=0.049
Expanded indication by other parameters 2 (40.0%)
Classic indication 17 (89.4%)
Cure by indication criteria (pairwise comparison 1)
Expanded indication: well-differentiated, intramucosal, 42cm 9 (64.3%) p=0.33
Expanded indication by other parameters 2 (40.0%)
Cure by indication criteria (pairwise comparison 2)
Expanded indication: well-differentiated, intramucosal, 42cm 9 (64.3%) p=0.094
Classic indication 17 (89.5%)
Cure by indication criteria (pairwise comparison 3)
Expanded indication by other parameters 2 (40.0%) p=0.042
Classic indication 17 (89.5%)
Adenocarcinoma differentiation grade
Well-differentiated 34 (89.5%)
Poorly differentiated 4 (10.5%)
Recurrence by differentiation grade
Well-differentiated 4 (11.7%) p=0.46
Poorly differentiated 1 (25.0%)
Recurrence by curative criteria
Classic criteria 0 (0.0%) p=0.014
Expanded criteria 1 (8.3%)
Noncurative criteria 4 (40.0%)
Recurrence by curative criteria (pairwise comparison 1)
Classic criteria 0 (0.0%) p=0.46
Expanded criteria 1 (8.3%)
Recurrence by curative criteria (pairwise comparison 2)
Classic criteria 0 (0.0%) p=0.019
Noncurative criteria 4 (40.0%)
Recurrence by curative criteria (pairwise comparison 3)
Expanded criteria 1 (8.3%) p=0.10
Noncurative criteria 4 (40.0%)
3
CLINICS 2018;73(supp 1):e553s. Valid crit for ESD of ECG 7 yrs exp west
Mendonc¸a EQ et al.
between patients meeting the classic (0%) and noncurative
criteria (40.0%), p=0.019.
’ DISCUSSION
In a previous study, a large series of patients from Eastern
countries who underwent ESD for treatment of EGC had en-
bloc and complete resection rates of 86% to 97% and 88% to
93%, respectively (17). These rates are the major parameters
for the evaluation of the short-term outcomes of ESD, and
they seem to correlate well with long-term prognosis (18).
Final staging can be carried out accurately only by formal
histological analysis, especially with regard to lymphovas-
cular infiltration. Therefore, en-bloc resection is a prerequisite
for accurate staging and the prediction of a patient’s risk of
lymph node metastasis (19). Japanese studies found local
recurrence rates of 10-15% after incomplete resection by ESD
but rates of 0-0.2% in patients with complete resection
(20,21), showing that an incomplete resection after ESD
should trigger the application of a complementary surgical
treatment.
In contrast, there is no long-term follow-up data available
from Western countries, and there is no consensus on whe-
ther the expanded resection criteria used in Eastern countries
can be adopted in the West (22). Comparing our experience
with the data from the abovementioned study, we found
similar a rate of en-bloc resection (92.1%) but a lower com-
plete resection rate (73.7%), with no difference between the
lesions that fulfilled the classic or expanded resection criteria.
This difference may be explained by the ESD learning curve.
It usually takes 30 procedures to be considered competent in
ESD. With a cumulative experience of 100 cases or more
of ESD, it would be possible to compare the results of the
first 30 cases with those of the remaining group. All patients
who did not achieve complete resection underwent surgical
treatment, except when other morbidities contraindicated
the procedure. In terms of recurrence, we found a higher
recurrence rate in the noncurative group than in group that
met the classic criteria.
Clarification is needed with regard to the analysis of the
group of patients who underwent ESD, met the expanded
criteria and were considered cured. Perhaps the most
relevant topic is the fact that this is a heterogeneous group.
In fact, we noticed a trend towards a higher chance of
noncurative criteria fulfillment for these lesions. However,
there was no difference when the expanded criteria were
limited to well-differentiated intramucosal adenocarcinomas
larger than 2 cm. We believe that the size of the lesion alone
might be one of the parameters that does not correlate with a
higher chance of an incomplete resection and a lower cure
rate. Previous findings from our group corroborate the
present results (23). It is possible that a refinement of the
expanded criteria with mucin expression characterization
may increase the accuracy of selecting the appropriate
patients for ESD (24).
Although we consider our experience and the obtained
data very relevant, especially because Brazil is a Western
country, this study had limitations due to its retrospec-
tive design and the fact that the data were obtained from a
single center. The sample size was also small, imposing a
limitation on the statistical power. New prospective studies
conducted in Western countries should address many of the
remaining doubts and issues related to endoscopic treatment
for ECG.
In conclusion, these results from a small ESD series con-
ducted in a cancer center in Brazil suggest that the expanded
criteria might be used for endoscopic treatment of EGC in
Western countries, especially for well-differentiated, intra-
mucosal adenocarcinomas larger than 2 cm.
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